SCHEMBL5528744

SCHEMBL5528744

Nc1ccc(Cl)cc1C(=O)c1ccccc1OCF

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.60
MAPT P10636 3/20 0.43
NOS2 P35228 1/20 0.42
RORC P51449 2/20 0.42
RORB Q92753 2/20 0.42
FADS1 O60427 1/20 0.42
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 2/20 0.41
GAA P10253 2/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
KCNMA1 Q12791 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6953541 0.86 RECQL (0.60) RECQLMAPTNOS2NPC1ALDH1A1
SCHEMBL6957797 0.84 PTGER1 (0.58) RECQLKDM4ENPC1KMT2APTGER1
SCHEMBL2705425 0.81 RECQL (0.65) RECQLMAPTRORCRORBKDM4E
SCHEMBL12165498 0.79 RECQL (0.61) RECQLMAPTKDM4EALDH1A1KMT2A
SCHEMBL9540049 0.78 RECQL (0.79) RECQLNOS2FADS1KDM4ENPC1
SCHEMBL12165534 0.78 RECQL (0.60) RECQLMAPTNOS2RORCRORB
SCHEMBL12165545 0.76 RECQL (0.48) RECQLMAPTNOS2FADS1NPC1
SCHEMBL1809103 0.76 MRGPRX1 (0.49) RECQLMAPTNOS2FADS1NPC1
SCHEMBL29515875 0.76 RECQL (0.71) RECQLMAPTNOS2FADS1KDM4E
SCHEMBL333224 0.76 RECQL (0.71) RECQLMAPTNOS2FADS1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2719698-A1 Methods for preparing aurora kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-04-16 EP disclosed
US-20070185087-A1 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185087-A1 Compounds and methods for inhibiting mitotic progression AURKC, AURKA, AURKB RECQL 414/4885MAPT 676/4885NOS2 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.